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Abstract
The interferon-inducible transmembrane (IFITM) family of proteins has been shown to restrict a broad range of
viruses in vitro and in vivo by halting progress through the late endosomal pathway. Further, single nucleotide
polymorphisms (SNPs) in its sequence have been linked with risk of developing severe influenza virus infections in
humans. The number of viruses restricted by this host protein has continued to grow since it was first demonstrated
as playing an antiviral role; all of which enter cells via the endosomal pathway. We therefore sought to test the limits
of antimicrobial restriction by Ifitm3 using a knockout mouse model. We showed that Ifitm3 does not impact on the
restriction or pathogenesis of bacterial (Salmonella typhimurium, Citrobacter rodentium, Mycobacterium tuberculosis)
or protozoan (Plasmodium berghei) pathogens, despite in vitro evidence. However, Ifitm3 is capable of restricting
respiratory syncytial virus (RSV) in vivo either through directly restricting RSV cell infection, or by exerting a
previously uncharacterised function controlling disease pathogenesis. This represents the first demonstration of a
virus that enters directly through the plasma membrane, without the need for the endosomal pathway, being
restricted by the IFITM family; therefore further defining the role of these antiviral proteins.
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Introduction
Intrinsic cellular defense molecules are able to detect and
restrict invading pathogens at the level of the infected cell and
constitute an initial repertoire of proteins that prevent infection.
Such intrinsic defenses have the ability to detect the pathogen,
and either directly block a component of the pathogen’s life
cycles and / or signal to the innate and adaptive immune
system to further control the infection. In certain cases, these
intrinsic restriction factors recognise non-self pathogen-
assocated molecular patterns, such as lipids, proteins and
nucleic acids, from a broad range of pathogens through
pathogen recognition receptors. This ability allows the host to
detect bacterial, viral, fungal and protozoan pathogens [1]. For
example, Toll-like receptor 4 alone is able to detect Gram-
negative bacteria, fungi, trypanosomes and surface proteins on
several viruses [2]. Alternatively, other restriction factors,
particularly those that target viruses, appear to have a more
reduced range of pathogens that they can block, as is the case
for many interferon-stimulated genes (ISGs) [3]. However,
restriction factors that work in defined cellular locations against
a common pathogen feature of infection may also have broad
anti-influenza properties.
We and others have found that the ISG interferon-inducible
transmembrane 3 (IFITM3), initially defined as playing a
developmental role in germ cell homing [4], has a profound role
in the restriction of viruses entering the cell through the acid
endosomal pathway [5,6], including influenza and dengue
viruses [7]. Since the discovery of IFITM3’s antiviral role, the
number of viruses restricted by the IFITM family has expanded
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considerably [5,7-14]. This has led to the generation of
hypotheses about how the IFITM family achieves restriction;
namely through preventing the fusion of viral and cellular
membranes [15,16].
Recently, the role of IFITM3 has been expanded by the
discovery of nonenveloped reoviruses’ restriction [9]. This has
important implications, as nonenveloped viruses do not rely on
membrane fusion to gain release from late endosomes.
Instead, it is hypothesised that these viruses may physically
disrupt the endosomal membrane through their surface
proteins [17,18]. This therefore potentially broadens the actions
of IFITM3 beyond enveloped viruses and may also include
other non-viral pathogens.
The role of IFITM3 in vivo shows it is crucial restriction factor
for preventing the onset of severe influenza viral infections in a
knockout mouse model [6]. Further, the overrepresentation of a
single nucleotide polymorphism (SNP), rs12252 C allele in the
human IFITM3 gene in two cohorts of patients hospitalised with
influenza virus during the 2009 H1N1 pandemic shows that the
rs12252 CC genotype confers an 4-5 fold increased risk
developing a severe influenza virus infection [6,19].
Here we sought therefore to expand and define the role of
Ifitm3 in pathogen restriction by assessing the susceptibility of
Ifitm3-deficient (Ifitm3-/-) mice to bacteria (Salmonella
Typhimurium, Citrobacter rodentium, Mycobacterium
tuberculosis), a parasite (Plasmodium berghei) and a virus
(respiratory syncytial virus, RSV) to determine the specificity of
this crucial antimicrobial protein. We show that Ifitm3 is
specifically an antiviral protein; yielding no significant
phenotype in mice when challenged with bacteria and
protozoa, despite studies implicating the IFITM family in
restriction of these pathogens [20,21].
We also show a novel role for Ifitm3 in vivo in restriction of
RSV: a virus that does not enter cells through the endosomal
pathway, adding further to the role of IFITM3 as a central
antiviral restriction factor that targets cellular entry.
Methods
Ethics statement
All animal experiments were conducted under Prof. Gordon
Dougan’s project licence No. 80/2596, entitled “The
characterization of microbial and murine genes required for
infection”. This was brought before the Wellcome Trust Sanger
Institute’s Animal Welfare and Ethical Review Body (formerly
known as the Ethical Review Committee) on 30th May 2012 and
approved. The WTSI’s Animal Welfare and Ethical Review
Body is constituted as required by the UK Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012.
Mice and general phenotyping
Background-matched 8-10 week old wild type, Ifitm3-/-
(Wellcome Trust Sanger Institute [22]) and Ifngr-/- mice
(Jackson Laboratories), all of which were >95% C57BL/6, were
maintained in accordance with UK Home Office regulations, UK
Animals Scientific Procedures Act 1986 under the project
license PPL 80/2596. Animals were supplied with food and
water ad libitum and were monitored daily for signs of illness.
Ifitm3-/- mice were phenotyped through pipelines at the
Wellcome Trust Sanger Institute as described previously
[23,24].
Immunohistochemistry
5-µm sections of paraffin-embedded tissue were incubated
with anti-Ifitm3 antibody (Abcam), which was subsequently
bound to a secondary horse radish peroxidase-conjugated anti-
rabbit antibody (Dako). Sections were counterstained with
hematoxylin (Sigma-Aldrich) and were assessed for expression
by microscopy.
Salmonella Typhimurium challenge
Groups of 8 Ifitm3-/- and 8 C57BL/6J mice were challenged
intravenously with 5 x 105 colony forming units (cfu) Salmonella
Typhimurium M525 containing TetC, (Fragment C of tetanus
toxin, to act as an antigen for subsequent antibody
quantification), and followed for 28 days. On day 14 post-
infection (pi), four from each group of mice are culled and
organs (spleen, liver and caecum) removed. A small piece of
the spleen and liver was fixed in 4% formalin and then later
processed to paraffin blocks as a biobank of infected tissue for
histological study if interesting. The rest of the organs were
weighed then homogenized, serially diluted and plated to
determine viable bacterial load. At day 28pi, the remaining four
mice are culled following a terminal bleed and the organs
removed and processed as above. The blood was allowed to
clot then centrifuged when the serum was removed and used
to detect TetC antigen specific antibodies by enzyme-linked
immuosorbent assay (ELISA). Mice were weighed and
monitored daily for signs of clinical illness.
Citrobacter rodentium challenge
Groups of 8 Ifitm3-/- and 8 C57BL6j mice were orally infected
by gavage with 1 x 109 cfu of and followed for 28 days. Every
2-3 days faeces from infected mice are collected. These were
then weighed and homogenized in 1 ml per 100 mg of faeces.
This was then serially diluted and plated to determine viable
bacterial load. On day 14pi four mice per group were culled
and organs (spleen, liver, caecal contents, caecum, 6cm of
colon) removed. A small piece of the distal colon was fixed in
4% formalin and processed to paraffin blocks as a biobank of
infected tissue for histological analysis. The rest of the organs
were weighed then homogenized, serially diluted and plated to
determine viable bacterial load. On day 28pi the remaining four
mice were culled and the above is repeated. Mice were
weighed and monitored daily for signs of clinical illness.
Mycobacterium tuberculosis challenge
Mice were infected by low-dose aerosol exposure with
H37Rv M. tuberculosis using a Glas-Col (Terre Haute, IN)
aerosol generator calibrated to deliver approximately 100
bacteria into the lungs. Bacterial counts in the lungs at each
time point of the study were determined by plating serial
dilutions of individual lung homogenates on duplicate plates of
Middlebrook 7H11 agar containing OADC enrichment. Colony-
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forming units were counted after 3–4 weeks incubation at
37 °C.
Plasmodium challenge
A transgenic Plasmodium berghei ANKA reporter line,
PbGFP-LUCCON (RMgm-28), that constitutively expresses a
fusion protein of GFP and Firefly Luciferase [25], was
maintained by passage in BALB/c mice. To induce
experimental cerebral malaria (ECM), infected blood containing
5 x 105 infected red blood cells was injected intraperitoneally.
From day six pi mice were monitored twice daily and scored for
clinical signs of neurologic disease using a ten parameter
murine coma and behaviour scale adapted from that of Carroll
et al. [26]. Mice classified as having ECM were killed by
cervical dislocation. On days 2 and 3 pi parasite growth was
monitored by luciferase measurements in 3 μl of blood, which
were collected from a tail vein into Citrate-dextrose ACD
freezing buffer (Sigma) and stored at -80°C until analysis using
the Promega Bright-Glo Luciferase assay System with a
Berthold Orion II microplate luminometer. Parasitemia was also
monitored using Giemsa-stained thin blood smears.
Cytokine quantification
Plasma samples from P. berghei infected mice were
analysed for cytokines using a Cytometric Bead Array
Inflammation kit (BD Biosciences) according to manufacturer’s
instructions.  Samples were acquired on a BD FACS Aria II,
and data analysed using BD FCAP array software.
Respiratory syncytial virus challenge
RSV strain A2 (from Prof P. Openshaw, Imperial College
London) was grown in HEp-2 cells and viral titer determined by
plaque assay. Mice were infected intranasally (i.n.) with 5 x 105
plaque forming units (PFU) under isoflurane anesthesia.
Weight was measured daily to monitor disease severity. To
collect bronchoalveolar lavage (BAL) fluid, the lungs of each
mouse were inflated five times with 1 ml of PBS and BAL fluid
kept on ice; 100 μl was centrifuged onto glass slides and
stained with hematoxylin and eosin for cell differentiation. The
remainder was centrifuged, the supernatant retained at −80°C,
and the pellet resuspended in RPMI medium with 10% fetal calf
serum. Lungs were removed, the smaller lobe was snap frozen
in liquid nitrogen for RNA extraction and the remainder was
homogenized by passage through 100-μm cell strainers
(Falcon). Red blood cells in the lung sample were lysed in
ammonium chloride buffer, and the remaining cells
resuspended in RPMI medium with 10% fetal calf serum.
Viable cell numbers were determined by trypan blue exclusion
and lung cells types were differentiated by flow cytometry on a
BD FACS Aria II using antibodies from BD and eBioscience.
RSV viral load was measured by quantitative RT-PCR for the
RSV L gene using primers and probes previously described
[27], with L gene copy number determined using a RSV L gene
standard and presented relative to μg lung RNA. Lungs were
homogenised with a rotor-stator homogeniser, centrifuged and
the supernatant collected for cytokine analyses. Cytokines in
lung homogenate and BAL fluid were quantified using duosets
from R&D systems.
Statistical analysis
All results are expressed as mean +/- S.D.; statistical
significance was calculated by analysis of variance (ANOVA)
followed by Bonferroni's Multiple Comparison Test when there
were more than two groups and Student’s t-tests for the
comparison of two groups. Non-normally distributed data were
assessed by Mann-Whitney U test. Results regarding mouse
survival were analysed by a Log-Rank (Mantel-Cox) test. All
data regarding mouse phenotyping, including how individual
traits were statistically analysed can be found at the Wellcome
Trust Sanger Institute’s Mouse Resources Portal (http://
www.sanger.ac.uk/mouseportal/) All calculations were
performed using GraphPad Prism 5.0 software, and results
were considered significant at p < 0.05.
Results
The role of Ifitm3 in murine homeostasis
Many genes are embryonically lethal or lead to no overt
phenotype when knocked out in mice. Indeed, Ifitm3-/- mice
have no discernable phenotype [22]. To examine in greater
detail, uninfected mice were assessed against a panel of
phenotypic assays [24], incorporating a robust set of adult traits
that are capable of detecting phenotypic variations. We
observed no statistically significant differences across all of our
key phenotyping categories, including those assessing immune
functions compared to wild type control mice (Table 1). Each of
the categories listed in Table 1 can be further subdivided into a
number of additional categories, again all being wild type in
phenotype. The complete list of phenotyping can be accessed
through the Wellcome Trust Sanger Institute’s Mouse
Resources portal (http://www.sanger.ac.uk/mouseportal/). We
assessed the tissue distribution of Ifitm3 by
immunohistochemistry of wild type compared to Ifitm3-/- mice,
including lymph node, lung, spleen, liver and intestine. The
expression of Ifitm3 was absent in all Ifitm3-/- mouse organs, as
expected, but was highly expressed in all wild type organs
(Figure 1).
In wild type mice, the expression pattern of Ifitm3 was
noteworthy. The spleen and lymph nodes indicated that Ifitm3
was predominantly expressed in the red pulp, but was absent
from the white pulp. Similarly, intestinal staining revealed Ifitm3
expression to be high in the lamina propria, but not on the villus
epithelium. Conversely, lung and liver showed ubiquitous
expression of Ifitm3 throughout the tissues, with protein present
in respiratory epithelial cells and hepatocytes, respectively.
As the first indication of the crucial role of IFITM3 only
appeared upon infection with influenza [6] and the tissue
distribution suggests Ifitm3 is important in multiple organ
systems, we challenged the Ifitm3-/- mice with a number of
different pathogens.
Salmonella Typhimurium challenge
Wild type and Ifitm3-/- mice were intravenously dosed with 1
× 106 CFU of S. Typhimurium M525 bacteria and observed for
28 days pi for signs of morbidity and weight loss (Figure 2A).
All mice survived the challenge and gained weight over the
time course of the study. Ifitm3-/- mice appeared to gain
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proportional weight at a slower rate, however, this was due to
these mice being on average 5g heavier at the start of
challenge and based on lack of bacterial counts and pathology,
is unlikely to be due to infection.
On day 28 pi, anti-S. Typhimurium antibody titres were
determined from the sera of wild type and Ifitm3-/- mice. This
indicated that both genotypes of mice produced statistically
similar antibody profiles (Figure 2B). Further, the bacterial load
was determined in the spleen, liver and faecal contents (Figure
2C-E). Similarly, bacterial counts revealed no significant
differences between wild type and Ifitm3-/- mice; together
showing that Ifitm3 does not play a role in resistance or
susceptibility to Salmonella infection.
Citrobacter rodentium challenge
Wild type and Ifitm3-/- mice were orally gavaged with 1 × 109
CFU of C. rodentium bacteria and monitored for 28 days pi for
signs of morbidity. Weight loss profiles showed that neither wild
type nor Ifitm3-/- mice had any overt signs of illness over the
course of infection (Figure 3A). Bacteria shed in the faeces of
these mice also revealed no significant differences between the
genotypes, with clearance of infection achieved by day 25 pi in
Ifitm3-/- mice (Figure 3B).
Mice were sacrificed on days 14 and 28 pi to determine any
differences in the bacterial burden between wild type and
Ifitm3-/- mice. Counts in the caecum (total, caeceal patch and
contents) and colon showed no significant differences in
bacterial colonisation and clearance (Figure 3C-F). Similarly,
analysis of the liver and spleen revealed no instances of
bacteraemia in either wild type or Ifitm3-/- mice (Figure 3G,H).
Taken together, these data suggest Ifitm3 does not impact on
C. rodentium infection or pathogenesis.
Table 1. Mammalian Phenotype (MP) ontology based
heatmap for Ifitm3-/- mice.
MP category MP category MP category MP category
Adipose tissue NS
Endocrine /
exocrine gland NS
Immune
system NS Pigmentation NS
Behaviour /
neurological NS Growth / size NS Integument NS
Renal /
urinary
system
NS
Cardiovascular
system NS
Haematopoetic
system NS
Limbs /
digits / tail NS
Reproductive
system NS
Cellular NS Hearing /vestibular / ear NS
Mortality /
ageing NS Skeleton NS
Craniofacial NS Homeostasis /metabolism NS
Nervous
system NS   
The heatmap is built up of top-level terms from the MP ontology, with a second tier
of tests included within each of the broader category headings listed in the table.
Significant results that deviate from the “normal” murine phenotype are indicated
by “S”, non-significant results are indicated by “NS”.
doi: 10.1371/journal.pone.0080723.t001
Mycobacterium tuberculosis challenge
Wild type and Ifitm3-/- mice were aerogenically infected with
an aerosolised dose of approximately 100 CFU of H37Rv M.
tuberculosis bacteria and monitored for signs of morbidity for
the following 28 days. To determine whether Ifitm3 was
involved in the control of the bacterial infection, mice were
sacrificed on days 0, 7, 14 and 28 pi to calculate the bacterial
burden in the lungs. There were however, no significant
differences between wild type and Ifitm3-/- mice (Figure 4), with
bacterial growth kinetics indicating that Ifitm3 does not effect on
M. tuberculosis infection and pathogenesis.
Plasmodium berghei challenge
Mice were intraperitoneally injected with 5 × 105 red blood
cells infected with a P. berghei ANKA reporter line, PbGFP-
LUCCON (RMgm-28), that constitutively expresses a fusion
protein of GFP and Firefly Luciferase [25]. Interferon gamma
(IFNγ) receptor knockout mice (Ifngr-/-) mice were included to
act as control, as these mice do not succumb to lethal episodes
of ECM. The experimental challenge revealed there to be no
significant difference in phenotype seen in Ifitm3-/- mice
compared with wild type littermate controls, with both showing
susceptibility to ECM (Figure 5A). The ~50% survival of wild
type mice falls within acceptable boundaries owing to inherent
inefficiencies in the delivery of parasites into the mice [28]. In
contrast, Ifngr-/- mice infected in parallel were fully protected
from infection. Analysis of parasite burden revealed that all
mice were infected with P. berghei (Figure 5B), but with no
significant differences at day three pi. Additionally, levels of the
inflammatory cytokines IFNγ, tumor necrosis factor alpha
(TNFα) and monocyte chemotactic protein-1 (MCP-1) were
analysed by cytometric bead array, again no significant
differences between wild type and Ifitm3-/- mice were observed
(Figure 5C).
RSV challenge
Wild type and Ifitm3-/- mice were intranasally infected with 5 ×
105 PFU of RSV-A (A2 strain) and were monitored daily for
weight loss for seven days pi. Cohorts of mice were sacrificed
on days four and seven pi to quantify viral burden and
immunological changes over the course of the challenge.
Ifitm3-/- mice showed highly significant weight loss on days
six and seven pi compared to wild type littermates (p < 0.01)
(Figure 6A). Furthermore, Ifitm3-/- mice showed a significantly
higher peak in viral load on day four pi (p < 0.05), which
remained higher than wild type mice at seven days pi (Figure
6B).
Bronchoalveolar lavage (BAL) was performed at days four
and seven pi and lungs harvested at day seven for cell and
cytokine measurements. Cellular infiltrate was quantified over
the course of infection, which showed a significant increase in
total cells resident in the lungs on day seven pi in Ifitm3-/- mice
(p < 0.05, Figure 6C) and a similarly significant increase in total
cellular infiltrate in the BAL fluid on day four pi (p < 0.01, Figure
6D). Flow cytometry revealed an increase in all cellular sub-
populations in Ifitm3-/- mice relative to wild type littermates on
day seven pi. In particular, numbers of total CD3+ T-cells (p <
0.05) in the lungs (Figure 6E) and granulocytes in the BAL fluid
Pathogens Restricted by Ifitm3
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e80723
Figure 1.  Expression of Ifitm3 at the predominant sites of pathogen infection.  Paraffin-embedded sections from wild type and
Ifitm3-/- mice were cut and stained for expression of Ifitm3 (brown), and counterstained with hematoxylin (blue). Original
magnification of lymph node and spleen 10×; lung and intestine 20×; liver 40×.
doi: 10.1371/journal.pone.0080723.g001
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(p < 0.01, Figure 6F). Analysis of inflammatory cytokines,
including IFNγ, IL-6 and IL-1β revealed differences in their
levels between genotypes of mice in the lungs and BAL fluid on
day seven pi (Figure 6G,H), with significantly higher levels of
IFNγ (lung: p < 0.05, BAL: p < 0.05) and IL-1β (p < 0.05) in
Ifitm3-/- mice relative to wild type controls.
Discussion
The role of IFITM3 in restricting virus infections, where the
virus enters the cell through the acidic endosomal pathway, is
well established [5,15,29]. However, IFITM3’s role in other
infections or the effect in removing IFITM3 in vivo in the
absence of infection is not well understood. Here we show
Ifitm3 is expressed in many different murine tissues and cell
types and does affect the response to RSV infection in mice.
Ifitm3 does not contribute to the infection phenotype of
Citrobacter, Salmonella or Mycobacterium bacterial infections.
These bacterial species encompass a range of physiological
and pathogenic niches. Salmonella enterica serovar
Typhimurium (S. Typhimurium) is an intracellular bacteria that
enters cells through phagocytosis or by a bacterial-triggered
entry mechanism and replicates within endosomal-like
structures known as Salmonella-containing vacuoles [30]. In
contrast, Citrobacter rodentium (C. rodentium) is a non-
invasive, Gram-negative bacterium used to model
enteropathogenic and enterohaemorrhagic  E. coli infections of
the gut [31,32], and Mycobacterium tuberculosis (M.
Figure 2.  Salmonella Typhimurium challenge of wild type and Ifitm3-/- mice.  Mice were intravenously injected with S.
Typhimurium and observed for weight loss for 28 days pi (A). Mice were killed on day 28 pi to assess neutralising antibody titre
against S. Typhimurium (B). Bacterial contents from spleen (C), liver (D) and caecal contents (E) were titred on days 14 and 28 pi to
assess the bacterial colonisation. ■: wild type, □: Ifitm3-/-. Results show means ± S.D. (n > 3).
doi: 10.1371/journal.pone.0080723.g002
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tuberculosis) is an intracellular respiratory bacterium that
replicates primarily within macrophages and dendritic cells,
before forming latent granulomas in the infected organs [33],
and is the causative agent of tuberculosis (TB). We found no
evidence for control of M. tuberculosis bacterial growth in
murine lungs, despite the fact that the pathogen triggers a type
I IFN response [34], which subsequently up-regulates Ifitm3
expression. Further, a recent study implicated a SNP
Figure 3.  Citrobacter rodentium challenge of wild type and Ifitm3-/- mice.  Mice were orally infected with C. rodentium and
weighed daily to monitor morbidity (A). Faecal samples were taken over the course of infection (B), and were homogenised, diluted
and plated to count the number of colony forming units (CFU) shed over the course of the challenge. Mice were also killed on days
14 and 28 pi and CFU of C. rodentium were counted from caecal patch (C), caecum (D), colon (E), caecal contents (F), liver (G) and
spleen (H). ■: wild type, □: Ifitm3-/-. Results show means ± S.D. (n > 4).
doi: 10.1371/journal.pone.0080723.g003
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(rs3888188) in the promoter of IFITM3 with susceptibility to TB
[21], wherein the minority rs3888188-G allele was significantly
overrepresented in patients with TB compared to healthy
controls in a Han Chinese population. We found no evidence in
our murine model that the ablation of Ifitm3 expression
impacted on M. tuberculosis infection. However, it should be
noted that we only assayed for initial infection and colonisation
of the lungs and that the long term dormancy characteristic of
human TB is not observed in the mouse model. Furthermore,
these differences may have arisen due to our challenge strain
differing from that used in the human study; therefore inducing
different gene expression signatures.
Further, we found that Ifitm3 does not impact on the
development of ECM in Plasmodium berghei ANKA infection,
although it is well established that malarial parasites elicit
strong type I and type II IFN responses in their hosts, which
have been shown to impact on the severity of infection [35,36],
with IFNα and IFNγ contributing to lethality in murine models.
Furthermore, eight SNPs in the IFN receptor, IFNAR1, have
been associated with the development of cerebral malaria in
children; a finding that is corroborated in Ifnar-/- mice, which
also do not develop cerebral malaria [37]. IFITM3, along with
several other ISGs, are significantly up-regulated in patients
that have become infected with P. falciparum [20]. It was
shown that deletion of several of these ISGs, including Tbk1
and the double knockout of Irf3 and Irf7 prevented mice from
developing lethal ECM [20,36]. Our work shows IFITM3 is not
an ISG involved in the pathogenesis of experimental cerebral
malaria.
Figure 4.  Bacterial growth kinetics of M. tuberculosis in
the lungs of wild type and Ifitm3-/- mice.  Mice were killed
over the course of infection with H37Rv M. tuberculosis to
determine the bacterial load within their lungs. ■: wild type, □:
Ifitm3-/-. Results show means ± S.D. (n > 5).
doi: 10.1371/journal.pone.0080723.g004
However, we saw that Ifitm3 was important in the control of
RSV infection, leading to more severe disease in Ifitm3-/- mice,
as assessed by weight loss, viral load and a dysregulated
immune response. Although these trends were seen with
influenza virus infection of Ifitm3-/- mice, the phenotype seen in
the RSV challenge is not as striking [6,38]. This may be due to
the response to the different viruses and the genetic
background of the mice (C57BL/6 Taconic), which we [39] and
others [40] have shown is influential in RSV disease severity.
RSV is one of the commonest respiratory pathogens in
children that necessitates hospitalisation [41]; accounting for
three times more admissions to hospital than influenza viruses
[42]. RSV, like influenza virus, is an enveloped virus that
initially causes a mild upper respiratory tract infection that can
develop into bronchiolitis and cause acute respiratory distress.
Our discovery that the lack of Ifitm3 can alter the
pathogenesis of RSV infection suggests IFITM3 either directly
restricts RSV cell infection in vivo, or exerts a hitherto
uncharacterised function controlling virus infection in vivo is
novel and supports associations seen in the mouse model
[43,44], in airway epithelial cultures [45] and in blood from
hospitalised infants [46]. Strikingly, RSV infects cells through
the plasma membrane and does not require the endosomal
pathway. RSV enters airway epithelial cells via F protein
binding of nucleolin, which is situated in cholesterol rich
microdomains / lipid rafts [47,48]. RSV is proposed to bind to
nucleolin via its F protein, which initiates hemifusion of the RSV
envelope with the cell membrane [48]; thus delivering the viral
content directly into the cytoplasm without the need for
endosomes.
Recently, Li and colleagues [49] suggested that the IFITM
family of proteins are capable of restricting viral hemifusion and
the formation of syncytia by reducing membrane fluidity [15,16].
Ifitm3, however, is primarily distributed intracellularly on
endosomal membranes [50]. Of the Ifitm family members,
Ifitm1 is primarily localised to the cell surface [15]: the site of
RSV-cell fusion. Therefore Ifitm1, which is functional in the
Ifitm3-/- mice [6], may provide the strongest block to RSV
infection. Previous studies have shown a degree of overlap of
function between IFITM1, -2 and -3, with certain IFITMs having
specificity for restricting particular viruses [7,8]. Importantly,
IFITM1, -2 and -3 interact and may function co-operatively [15],
possibly with IFITM3 potentiating an IFITM1 restriction of RSV.
Indeed, Ifitm1 has been shown to be up-regulated during RSV
infection [51].
With the recent recognition of IFITM3-mediated restriction of
nonenveloped reoviruses, the pleotropic effect of IFITM3 on
diverse virus infections, or the co-operative role of all antiviral
IFITM proteins as a layered defense to different virus
infections, remains to be determined.
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Figure 5.  Malarial challenge of wild type and Ifitm3-/- mice with P. berghei ANKA.  Mice were intraperitoneally injected with red
blood cells containing P. berghei ANKA and were monitored for survival for 12 days pi. n = 9 for wild type, n = 2 for each of Ifitm3-/-
and Ifngr-/- mutants (A). Parasite biomass was monitored by measuring the activity of a luciferase reporter gene constitutively
expressed by the parasite and expressed as relative light units (RLU) (B), and cytokine dysregulation was measured from the sera
on day three pi by cytometric bead assay (C). ■: wild type, □: Ifitm3-/-, ○: Ifngr-/-. Results show means ± S.D. (n > 2).
doi: 10.1371/journal.pone.0080723.g005
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Figure 6.  Comparison of RSV infection in Ifitm3-/- mice to wild type mice.  Ifitm3-/- or wild type littermate control mice were
infected i.n. with 5x105 RSV A2. Mice were weighed daily and weight changes recorded as a percentage of original weight (A).
Lungs were excised and viral load calculated by qPCR on days 4 and 7 pi (B). Total cell counts from lung (C) and BAL (D) were
calculated, along with totals of CD3, CD4 and CD8 (T cells), CD19 (B cells) and DX5+ (NK cells) (E) measured in lung by flow
cytometry on day 7 post infection. Granulocyte numbers were also calculated in the BAL on day 7 post infection (F) Levels of the
inflammatory cytokines IFNγ and IL-1β in lung (G) and IFNγ and IL-6 in BAL (H) were measured by ELISA on day 7 post infection.
■: wild type, □: Ifitm3-/-. Results show means ± S.D. (n > 5). Statistical significance was assessed by Student’s t-test, or ANOVA
followed by Bonferroni's Multiple Comparison Test when there were more than two groups (* p<0.05, ** p<0.01, *** p<0.001).
doi: 10.1371/journal.pone.0080723.g006
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